Trial Profile
A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Registrational; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 05 Oct 2017 Status changed from not yet recruiting to completed.
- 29 Sep 2016 New trial record